Endeavor Zotarolimus - Eluting Stent in the Treatment Lesions in Small Native Coronary Arteries. (ENDEAVORSVS)

This study has been completed.
Information provided by (Responsible Party):
Medtronic Vascular
ClinicalTrials.gov Identifier:
First received: January 25, 2008
Last updated: January 26, 2015
Last verified: January 2015

January 25, 2008
January 26, 2015
January 2008
March 2012   (final data collection date for primary outcome measure)
  • In-segment percent diameter stenosis at 8 months post-procedure [ Time Frame: 8 months post-procedure ] [ Designated as safety issue: No ]
    In-segment percent diameter stenosis at 8 months post-procedure with percent diameter stenosis defined as the value calculated as 100 x (RVD - Minimal Lumen Diameter (MLD)/RVD using the mean values from two orthogonal views (when possible) by Qualitative Coronary Angiography (QCA).
  • Major Adverse Cardiac Events (MACE) Rate [ Time Frame: 12 months post-procedure ] [ Designated as safety issue: Yes ]
    Major Adverse Cardiac Events rate at 12 months post-procedure defined as death, target-vessel Myocardial Infarction (Q wave and non-Q wave), emergent cardiac bypass surgery, or target lesion revascularization, repeat percutaneous transluminal coronary angioplasty or cardiac bypass surgery.
In-segment percent diameter stenosis at 8 months post-procedure [ Time Frame: 8 months ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00609947 on ClinicalTrials.gov Archive Site
Not Provided
Major Adverse Cardiac Events (MACE) rate [ Time Frame: 12 months post-procedure ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Endeavor Zotarolimus - Eluting Stent in the Treatment Lesions in Small Native Coronary Arteries.
A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries

The objective of this study is to verify the safety and efficacy of the Endeavor Zotarolimus-Eluting Coronary Stent System for improving coronary luminal diameter in patients with ischemic heart disease due to de novo lesions of length ≤27 mm in native coronary arteries with reference vessels ≥ 2.25 mm to ≤ 2.75 mm.

Not Provided
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Coronary Artery Disease
Device: Endeavor Zotarolimus-Eluting Coronary Stent
Other Name: Endeavor
Experimental: Endeavor Zotarolimus-Eluting Coronary Stent
Zotarolimus-eluting stent (ZES) implanted using standard percutaneous coronary intervention (PCI) technique via the femoral approach
Intervention: Device: Endeavor Zotarolimus-Eluting Coronary Stent
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
September 2013
March 2012   (final data collection date for primary outcome measure)


  • The patient is ≥18 years of age.
  • The patient has clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, or positive functional study.
  • The patient is an acceptable candidate for Percutaneous Transluminal Coronary Angiography (PTCA), stenting, and emergent Coronary Artery Bypass Grafting (CABG) surgery.
  • Female patients of childbearing potential must have a negative pregnancy test within 7 days before the procedure.
  • The patient or patient's legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board of the respective clinical site.
  • The patient agrees to return to same research facility for all required post-procedure follow-up visits.


1. The target lesion/vessel must meet the following criteria:

  1. The patient requires treatment of either:

    • A single de novo lesion located in a native coronary artery amenable to treatment with a 2.25mm, 2.5mm or 2.75mm stent, or
    • Two de novo lesions located in separate target vessels, with at least one of the target lesions amenable to treatment with a 2.25mm, 2.5mm, or 2.75mm stent and the second lesion amenable to treatment with a 2.25mm, 2.5mm, or 2.75mm stent or a 3.0mm or 3.5mm approved Endeavor stent.
  2. The lesion(s) must be ≤ 27mm in length.
  3. The lesion(s) must have a stenosis of ≥ 50% and < 100%.
  4. The vessel(s) has (have) a thrombolysis in myocardial infarction (TIMI) flow 2 or greater.
  5. The target vessel reference diameter must be ≥ 2.25mm and ≤ 2.75mm and the second target vessel reference diameter, if present, must be ≥ 2.25mm and ≤ 3.5mm.
  6. All target lesions can be treated with a Medtronic Endeavor stent.


  1. Known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, ticlopidine, clopidogrel, cobalt, nickel, chromium, molybdenum, polymer coatings, or sensitivity to contrast media, which cannot be adequately pre-medicated
  2. History of allergic reaction or significant sensitivity to drugs such as zotarolimus, rapamycin, tacrolimus, everolimus, or any other analogue or derivative
  3. Platelet count <100,000 cells/mm³ or >700,000 cells/mm³, or white blood cell count <3,000 cells/mm³
  4. Serum creatinine level >2.0 mg/dl within 7 days prior to index procedure
  5. Evidence of acute MI within 72 hours of intended index procedure
  6. Planned PCI of any vessel within 30 days pre or post-index procedure and/or planned PCI of the target vessel(s) within 12 months post-procedure.
  7. During the index procedure, the target lesion(s) requires treatment with a device other than PTCA prior to stent placement
  8. History of stroke or transient ischemic attack (TIA) within prior 6 months
  9. Active peptic ulcer or upper gastrointestinal (GI) bleeding within prior 6 months.
  10. History of bleeding diathesis or coagulopathy or patient will refuse blood transfusions.
  11. Concurrent medical condition with life expectancy of less than 12 months.
  12. Any previous or planned treatment of target vessel with anti-restenotic therapies including but not limited to brachytherapy.
  13. Currently participating in an investigational drug or another device study that has not completed primary endpoint or that clinically interferes with current study endpoints; or requires coronary angiography, IVUS or other coronary artery imaging procedures.
  14. Documented left ventricular ejection fraction (LVEF) <30% at most recent evaluation.
  15. Inability to comply with protocol required medication regimen ANGIOGRAPHIC EXCLUSION CRITERIA

1. Target lesion(s) located in native vessel distal to anastomosis with saphenous vein graft or a left/right internal mammary artery bypass with >40% diameter stenosis anywhere within graft.

2. Previous stenting in the target vessel(s) unless the following conditions are met:

a. It has been at least 9 months since the previous stenting, and b. The target lesion(s) is/are at least 15mm away from the previously placed stent.

3. Target vessel has other lesions with >40% diameter stenosis based on visual estimate or on-line QCA 4. Target vessel(s) has/have evidence of thrombus 5. Target vessel(s) is excessively tortuous (two bends ≥90º to reach target lesion) 6. Target lesion has any of the following characteristics:

  1. Location is aorto-ostial, an unprotected left main lesion, or within 5 mm of the origin of the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA)
  2. Involves a side branch >2.0 mm in diameter
  3. Is at or distal to a >45º bend in the vessel
  4. Is severely calcified
  5. Involves a bifurcation 7. Unprotected left main coronary artery disease
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
Medtronic Vascular
Medtronic Vascular
Not Provided
Principal Investigator: Martin B Leon, MD Columbia University College of Physicians and Surgeons
Medtronic Vascular
January 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP